about
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Systemic adjuvant therapies in renal cell carcinoma
@ast
Systemic adjuvant therapies in renal cell carcinoma
@en
type
label
Systemic adjuvant therapies in renal cell carcinoma
@ast
Systemic adjuvant therapies in renal cell carcinoma
@en
prefLabel
Systemic adjuvant therapies in renal cell carcinoma
@ast
Systemic adjuvant therapies in renal cell carcinoma
@en
P2860
P356
P1433
P1476
Systemic adjuvant therapies in renal cell carcinoma
@en
P2093
Andrea Ardizzoni
Maddalena Donini
P2860
P356
10.4081/ONCOL.2012.E18
P577
2012-10-08T00:00:00Z